[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR053913A1 - Cepa atenuada de dengue serotipo 1 - Google Patents

Cepa atenuada de dengue serotipo 1

Info

Publication number
AR053913A1
AR053913A1 ARP060102566A ARP060102566A AR053913A1 AR 053913 A1 AR053913 A1 AR 053913A1 AR P060102566 A ARP060102566 A AR P060102566A AR P060102566 A ARP060102566 A AR P060102566A AR 053913 A1 AR053913 A1 AR 053913A1
Authority
AR
Argentina
Prior art keywords
strain
dengue serotype
dengue
damaged strain
vdv1
Prior art date
Application number
ARP060102566A
Other languages
English (en)
Inventor
Richard M Kinney
Claire Y Huang
Veronique Barban
Jean Lang
Bruno Guy
Original Assignee
Ct S For Desease Control And P
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct S For Desease Control And P, Sanofi Pasteur filed Critical Ct S For Desease Control And P
Publication of AR053913A1 publication Critical patent/AR053913A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a cepas de VDV1 (virus dengue serotipo 1 derivado de Vero) atenuadas vivas, que derivan de la cepa de dengue-1 de tipo silvestre 16007 por pasaje en células PDK y sanitizacion en células Vero. La invencion también se refiere a una composicion de vacuna que comprende una cepa de VDV1.
ARP060102566A 2005-06-17 2006-06-16 Cepa atenuada de dengue serotipo 1 AR053913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69124305P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
AR053913A1 true AR053913A1 (es) 2007-05-23

Family

ID=36933493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102566A AR053913A1 (es) 2005-06-17 2006-06-16 Cepa atenuada de dengue serotipo 1

Country Status (16)

Country Link
US (3) US7641907B2 (es)
EP (1) EP1893637B1 (es)
JP (1) JP5197362B2 (es)
KR (2) KR101536612B1 (es)
CN (1) CN101238144B (es)
AR (1) AR053913A1 (es)
AU (1) AU2006257610B2 (es)
BR (1) BRPI0613328A2 (es)
CA (1) CA2611934C (es)
IL (1) IL188041A0 (es)
MX (1) MX2007015873A (es)
MY (1) MY144689A (es)
NO (1) NO20076355L (es)
TW (1) TWI414605B (es)
WO (1) WO2006134433A1 (es)
ZA (1) ZA200710714B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122018075730B1 (pt) 2002-01-15 2022-04-19 Acambis, Inc Flavivírus na preparação de uma composição de vacina e composição de vacina
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2009109550A1 (en) 2008-03-05 2009-09-11 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2011026139A1 (en) 2009-08-31 2011-03-03 Gen-Probe Incorporated Dengue virus assay
CA2878682A1 (en) 2012-07-24 2014-01-30 Alain Bouckenooghe Vaccine compositions for use in a method of protecting a human subject against dengue disease
CN104812408A (zh) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
CA2933472A1 (en) * 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
HUE061507T2 (hu) 2013-03-15 2023-07-28 Takeda Vaccines Inc Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz
SG11201510266SA (en) 2013-06-21 2016-01-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
MX2017008342A (es) 2014-12-22 2017-10-24 Merck Sharp & Dohme Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
CA3005814C (en) * 2015-11-27 2022-09-27 The Chemo-Sero-Therapeutic Research Institute Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ATE419006T1 (de) * 1999-03-26 2009-01-15 Us Army Multivalenter dengue-virus impfstoff
PT2278012E (pt) * 2000-02-16 2015-11-30 Univ Mahidol Quimeras imunogénicas do vírus do dengue 2
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
KR100927517B1 (ko) * 2000-09-25 2009-11-17 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 생균 백신
ES2533085T3 (es) 2001-05-22 2015-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
EP3763382A1 (en) * 2002-05-03 2021-01-13 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
JP4537045B2 (ja) * 2003-12-11 2010-09-01 キヤノン株式会社 電子ペーパー、電子ペーパー接続装置、システム、電子ペーパーにおける制御方法及びコンピュータプログラム

Also Published As

Publication number Publication date
TW200741002A (en) 2007-11-01
US20060292172A1 (en) 2006-12-28
ZA200710714B (en) 2008-11-26
JP2008546382A (ja) 2008-12-25
JP5197362B2 (ja) 2013-05-15
US7641907B2 (en) 2010-01-05
US8067565B2 (en) 2011-11-29
CA2611934C (en) 2015-11-03
NO20076355L (no) 2008-03-11
US20100137571A1 (en) 2010-06-03
US9169298B2 (en) 2015-10-27
IL188041A0 (en) 2008-03-20
AU2006257610A1 (en) 2006-12-21
MY144689A (en) 2011-10-31
EP1893637B1 (en) 2016-01-06
EP1893637A1 (en) 2008-03-05
US20120083584A1 (en) 2012-04-05
AU2006257610B2 (en) 2012-11-15
CA2611934A1 (en) 2006-12-21
CN101238144A (zh) 2008-08-06
BRPI0613328A2 (pt) 2011-01-04
KR101536612B1 (ko) 2015-07-14
WO2006134433A1 (en) 2006-12-21
TWI414605B (zh) 2013-11-11
KR20080027356A (ko) 2008-03-26
CN101238144B (zh) 2012-09-05
KR101464649B1 (ko) 2014-12-01
MX2007015873A (es) 2008-04-22
KR20140006119A (ko) 2014-01-15

Similar Documents

Publication Publication Date Title
AR053913A1 (es) Cepa atenuada de dengue serotipo 1
AR053914A1 (es) Cepa atenuada del dengue serotipo 2
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
PH12015500773A1 (en) Methods and compositions for live attenuated viruses
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
CL2011000502A1 (es) Composicion que comprende al menos una bacteria formadora de esporas, al menos un agente para combatir insectos y un disolvente; y procedimiento proteger una semilla, parte vegetal o planta geneticamente modificada de nematodos basado en la aplicacion de la composicion descrita anteriormente.
CR9076A (es) Metodo y materiales para conferir resistencia a las pestes y patogenos de plantas
BRPI0908489A2 (pt) uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengue
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
SG170751A1 (en) Extractions and methods comprising elder species
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
MX2009003378A (es) Concentrados en suspension para la mejora de la absorcion por la raiz de principios activos agroquimicos.
UY32274A (es) Pestivirus quimericos
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
AR072976A1 (es) Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
ES2585242T3 (es) Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
AR061197A1 (es) Cepas del virus 3 del dengue vivas atenuadas

Legal Events

Date Code Title Description
FB Suspension of granting procedure